US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jul 2, 2013 (13 years ago)

Cholecalciferol

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mixup: CHOLECALCIFEROL, Capsule, 2000 units may have potentially been mislabeled as one of the following drugs: DOXYCYCLINE HYCLATE, Tablet, 100 mg, NDC 53489012002, Pedigree: AD30993_8, EXP: 5/9/2014; VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 50 mg, NDC 40985022251, Pedigree: AD60211_20, EXP: 5/21/2014; lamoTRIgine, Tablet, 50 mg (1/2 of 100 mg), NDC 13668004701, Pedigree: A

What was recalled

CHOLECALCIFEROL, Capsule, 2000 units, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536379001.

Recalling firm
Aidapak Services, LLC
Origin
WA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-937-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Cholecalciferol recalls

See all
Class II · Moderate risk Terminated

Cholecalciferol

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0198-2023
Class II · Moderate risk Terminated

Vitamin D3 Cholecalciferol 50

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 75834-020-12 D-0532-2021
Class II · Moderate risk Terminated

Vitamin D3 Cholecalciferol 50

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 75834-020-01 D-0531-2021
Class II · Moderate risk Terminated

Cholecalciferol

Reason Lack of Assurance of Sterility

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0251-3 D-0993-2020
Class II · Moderate risk Terminated

Cholecalciferol

Reason Lack of Assurance of Sterility

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0210-3 D-0992-2020